Recently, several diagnostic tests like Genomind, MedClueRx, and GeneSight Psychotropic have been developed to further treat depression. Patients’ genes are observed to predict how they will respond to a specific medication. Initially, the tests seem to provide a solution that could alleviate symptoms for patients living with depression, but limited evidence and unreasonable costs could flaw the idea.
Dr. Robert Klitzman, Academic Director of the Master of Science in Bioethics program, says, "The problem is there's a lot of hype.” He adds that treating mental illness is complicated because there remains “a lot about the brain we don’t know.”
Read the full story at Mashable and learn more about the M.S. in Bioethics program at Columbia University’s School of Professional Studies.
